Food and Behaviour Research

Donate Log In

ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment.

Fiala M, Halder RC, Sagong B, Ross O, Sayre J, Porter V, Bredesen DE (2015) FASEB J.  29 (4)  doi: 10.1096/fj.14-264218 

Web URL: Read more and find related articles on the PubMed website here

Abstract:

We investigated the effects of 4-17 month supplementation with ω-3 fatty acids and antioxidants (Smartfish drink; Smartfish AS, Oslo, Norway) in 12patients with minor cognitive impairment (MCI) [minimental state examination (MMSE) ≥19], 2 patient with pre-MCI s (normal MMSE), and 7 patientswith Alzheimer disease (AD) (MMSE <19).

We measured the 
phagocytosis of amyloid-β 1-42 (Aβ) by flow cytometry and microscopy, the transcription of inflammatory genes by RT-PCR, the production of resolvin D1 (RvD1) by enzyme immunoassay, and the cognitive status by MMSE.

In 
patients with MCI and pre-MCI, phagocytosis of Aβ by monocytes increased from 530 to 1306 mean fluorescence intensity units (P = 0.016). The increase in patients with AD was not significant (N.S.).

The lipidic mediator RvD1, which stimulates Aβ 
phagocytosis in vitro, increased in macrophages in 80% ofpatients with MCI and pre-MCI (mean increase 9.95 pg/ml) (N.S.).

Transcription of inflammatory genes' mRNAs was increased in a subgroup of
patients with low transcription at baseline, whereas it was not significantly changed in patients with high transcription at baseline.

The mean MMSE score of 
patients with MCI and pre-MCI was 25.9 at baseline and 25.7 after 4-17 months (N.S.).

Our study is the first to show significant immune and biochemical effects of ω-3 fatty acids with antioxidants in 
patients with MCI. 

Cognitive benefits of ω-3 supplementation in patients with MCI should be tested in a clinical trial.